UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Clinical trials for UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Cancer vaccine boosts immunotherapy in advanced lung and Head/Neck tumors
Disease control OngoingThis study tests a vaccine called CIMAvax combined with immunotherapy drugs (nivolumab or pembrolizumab) in people with advanced non-small cell lung cancer or head/neck cancer that has spread. The goal is to find the best dose and see if the combination helps control tumor growth…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 26, 2026 07:00 UTC
-
New combo aims to shrink lung tumors when immunotherapy fails
Disease control OngoingThis study tests a new drug called pevonedistat combined with standard chemotherapy (carboplatin and paclitaxel) in people with advanced non-small cell lung cancer that has not responded to immunotherapy. The goal is to see if this combination can shrink tumors or slow cancer gro…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:59 UTC
-
New drug combo shows promise for Hard-to-Treat lung cancer
Disease control OngoingThis study is for people with advanced non-small cell lung cancer that has come back or spread. It tests a combination of two drugs: trametinib, which blocks cancer cell growth, and pembrolizumab, which helps the immune system attack cancer. The goal is to see if this combination…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 06:59 UTC
-
New drug cocktail targets Hard-to-Treat lung cancer
Disease control OngoingThis early-phase study tests a new combination of two drugs, minnelide and osimertinib, for people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). The main goal is to find the safest dose and see how the body responds. Only 8 participants…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 06:43 UTC
-
Immunotherapy duo plus radiation shows promise in lung cancer trial
Disease control OngoingThis early-phase trial is testing whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for people with stage II or III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this approach ca…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Experimental combo aims to boost Radiation's punch against returning lung tumors
Disease control OngoingThis early-phase study tests a drug called NBTXR3, which makes cancer cells more sensitive to radiation, combined with a second round of radiation for people whose non-small cell lung cancer has returned and cannot be removed by surgery. The main goals are to find the safest dose…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
Could adding durvalumab early beat lung cancer?
Disease control OngoingThis study tests whether adding the immunotherapy drug durvalumab to standard chemoradiation (and continuing it afterward) helps people with stage 3 lung cancer that can't be surgically removed live longer or keep the cancer from coming back. About 660 adults with newly diagnosed…
Matched conditions: UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:00 UTC